These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 34992532)

  • 1. Empagliflozin Reduces Renal Hyperfiltration in Response to Uninephrectomy, but Is Not Nephroprotective in UNx/DOCA/Salt Mouse Models.
    Tauber P; Sinha F; Berger RS; Gronwald W; Dettmer K; Kuhn M; Trum M; Maier LS; Wagner S; Schweda F
    Front Pharmacol; 2021; 12():761855. PubMed ID: 34992532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice.
    Vallon V; Gerasimova M; Rose MA; Masuda T; Satriano J; Mayoux E; Koepsell H; Thomson SC; Rieg T
    Am J Physiol Renal Physiol; 2014 Jan; 306(2):F194-204. PubMed ID: 24226524
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic effects of lisinopril and empagliflozin in a mouse model of hypertension-accelerated diabetic kidney disease.
    Østergaard MV; Secher T; Christensen M; Salinas CG; Roostalu U; Skytte JL; Rune I; Hansen HH; Jelsing J; Vrang N; Fink LN
    Am J Physiol Renal Physiol; 2021 Aug; 321(2):F149-F161. PubMed ID: 34180715
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SGLT2 Inhibitors and the Diabetic Kidney.
    Fioretto P; Zambon A; Rossato M; Busetto L; Vettor R
    Diabetes Care; 2016 Aug; 39 Suppl 2():S165-71. PubMed ID: 27440829
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition.
    Vallon V; Thomson SC
    Diabetologia; 2017 Feb; 60(2):215-225. PubMed ID: 27878313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heme arginate therapy enhanced adiponectin and atrial natriuretic peptide, but abated endothelin-1 with attenuation of kidney histopathological lesions in mineralocorticoid-induced hypertension.
    Ndisang JF; Jadhav A
    J Pharmacol Exp Ther; 2010 Jul; 334(1):87-98. PubMed ID: 20392817
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injury.
    Aroor AR; Das NA; Carpenter AJ; Habibi J; Jia G; Ramirez-Perez FI; Martinez-Lemus L; Manrique-Acevedo CM; Hayden MR; Duta C; Nistala R; Mayoux E; Padilla J; Chandrasekar B; DeMarco VG
    Cardiovasc Diabetol; 2018 Jul; 17(1):108. PubMed ID: 30060748
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [EMPA-KIDNEY: empagliflozin in chronic kidney disease].
    Delanaye P; Scheen AJ
    Rev Med Liege; 2023 Jan; 78(1):24-28. PubMed ID: 36634063
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The kidney and cardiovascular outcome trials.
    Bloomgarden Z
    J Diabetes; 2018 Feb; 10(2):88-89. PubMed ID: 29031006
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Empagliflozin increases kidney weight due to increased cell size in the proximal tubule S3 segment and the collecting duct.
    Sinha F; Federlein A; Biesold A; Schwarzfischer M; Krieger K; Schweda F; Tauber P
    Front Pharmacol; 2023; 14():1118358. PubMed ID: 37033639
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sodium-glucose cotransporter 2 inhibition prevents renal fibrosis in cyclosporine nephropathy.
    Castoldi G; Carletti R; Ippolito S; Colzani M; Barzaghi F; Stella A; Zerbini G; Perseghin G; Zatti G; di Gioia CRT
    Acta Diabetol; 2021 Aug; 58(8):1059-1070. PubMed ID: 33760995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Knockout of Na-glucose transporter SGLT2 attenuates hyperglycemia and glomerular hyperfiltration but not kidney growth or injury in diabetes mellitus.
    Vallon V; Rose M; Gerasimova M; Satriano J; Platt KA; Koepsell H; Cunard R; Sharma K; Thomson SC; Rieg T
    Am J Physiol Renal Physiol; 2013 Jan; 304(2):F156-67. PubMed ID: 23152292
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EMPA-KIDNEY: expanding the range of kidney protection by SGLT2 inhibitors.
    Fernández-Fernandez B; Sarafidis P; Soler MJ; Ortiz A
    Clin Kidney J; 2023 Aug; 16(8):1187-1198. PubMed ID: 37529652
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Empagliflozin alleviates podocytopathy and enhances glomerular nephrin expression in
    Klimontov VV; Korbut AI; Taskaeva IS; Bgatova NP; Dashkin MV; Orlov NB; Khotskina AS; Zavyalov EL; Klein T
    World J Diabetes; 2020 Dec; 11(12):596-610. PubMed ID: 33384767
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modeling the renoprotective mechanisms of SGLT2 inhibition in hypertensive chronic kidney disease.
    Clemmer JS; Yen TE; Obi Y
    Physiol Rep; 2023 Nov; 11(21):e15836. PubMed ID: 37957121
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduced Krüppel-Like Factor 2 Aggravates Glomerular Endothelial Cell Injury and Kidney Disease in Mice with Unilateral Nephrectomy.
    Zhong F; Mallipattu SK; Estrada C; Menon M; Salem F; Jain MK; Chen H; Wang Y; Lee K; He JC
    Am J Pathol; 2016 Aug; 186(8):2021-2031. PubMed ID: 27317905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sodium/glucose cotransporter 2 inhibitors and prevention of diabetic nephropathy: targeting the renal tubule in diabetes.
    De Nicola L; Gabbai FB; Liberti ME; Sagliocca A; Conte G; Minutolo R
    Am J Kidney Dis; 2014 Jul; 64(1):16-24. PubMed ID: 24673844
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renal Anti-Fibrotic Effect of Sodium Glucose Cotransporter 2 Inhibition in Angiotensin II-Dependent Hypertension.
    Castoldi G; Carletti R; Ippolito S; Colzani M; Barzaghi F; Stella A; Zerbini G; Perseghin G; di Gioia CRT
    Am J Nephrol; 2020; 51(2):119-129. PubMed ID: 31910407
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The SGLT2 Inhibitor Empagliflozin Might Be a New Approach for the Prevention of Acute Kidney Injury.
    Chu C; Lu YP; Yin L; Hocher B
    Kidney Blood Press Res; 2019; 44(2):149-157. PubMed ID: 30939483
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravital imaging of hemodynamic glomerular effects of enalapril or/and empagliflozin in STZ-diabetic mice.
    Kroeger H; Kessel F; Sradnick J; Todorov V; Gembardt F; Hugo C
    Front Physiol; 2022; 13():982722. PubMed ID: 36171965
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.